The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Cisplatin resistance: Preclinical findings and clinical implications
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Kunkel, T. A., & Erie, D. A. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133243 · Cited by 1,367
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Mammalian DNA nucleotide excision repair reconstituted with purified protein components
Aboussekhra, A., Biggerstaff, M., Shivji, M. K. K., Vilpo, J. A., Moncollin, V., Podust, V. N., Protić, M., Hübscher, U., Egly, J.-M., & Wood, R. D. (1995) · Cell · doi:10.1016/0092-8674(95)90289-9 · Cited by 837
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Kaina, B., Christmann, M., Naumann, S., & Roos, W. P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 663
Self-citationCellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Molecular Mechanisms of Mammalian Global Genome Nucleotide Excision Repair
Gillet, L. C. J., & Schärer, O. D. (2006) · Chemical Reviews · doi:10.1021/cr040483f · Cited by 642 · cited 1×
“pyrimidine dimers and 6-4 photoproducts and DNA lesions induced by many chemotherapeutic drugs [47–49].”
BackgroundRixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
Ohndorf, U.-M., Rould, M. A., He, Q., Pabo, C. O., & Lippard, S. J. (1999) · Nature · doi:10.1038/21460 · Cited by 565
Xeroderma Pigmentosum Group F Caused by a Defect in a Structure-Specific DNA Repair Endonuclease
Sijbers, A. M., de Laat, W. L., Ariza, R. R., Biggerstaff, M., Wei, Y.-F., Moggs, J. G., Carter, K. C., Shell, B. K., Evans, E., de Jong, M. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80155-5 · Cited by 548
Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.309 · Cited by 505
Niedernhofer, L. J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A. F., de Wit, J., Jaspers, N. G. J., Beverloo, H. B., Hoeijmakers, J. H. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5776-5787.2004 · Cited by 492
Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., & Reed, E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117388 · Cited by 446
Cobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J. M., Provencio, M., Viñolas, N., Paz-Ares, L., Lopez-Vivanco, G., Muñoz, M. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7915 · Cited by 443
Identification of XAF1 as an antagonist of XIAP anti-Caspase activity
Liston, P., Fong, W. G., Kelly, N. L., Toji, S., Miyazaki, T., Conte, D., Tamai, K., Craig, C. G., McBurney, M. W., & Korneluk, R. G. (2001) · Nature Cell Biology · doi:10.1038/35055027 · Cited by 441
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Duckett, D. R., Drummond, J. T., Murchie, A. I., Reardon, J. T., Sancar, A., Lilley, D. M., & Modrich, P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6443 · Cited by 421
Molecular mechanisms involved in cisplatin cytotoxicity
Jordan, P., & Carmo-Fonseca*, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000762 · Cited by 398
Mansouri, A., Ridgway, L. D., Korapati, A. L., Zhang, Q., Tian, L., Wang, Y., Siddik, Z. H., Mills, G. B., & Claret, F. X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208134200 · Cited by 377
Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance
McHugh, P. J., Spanswick, V. J., & Hartley, J. A. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00454-5 · Cited by 376
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Strathdee, G., MacKean, M. J., Illand, M., & Brown, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202540 · Cited by 350
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
Kato, J., Kuwabara, Y., Mitani, M., Shinoda, N., Sato, A., Toyama, T., Mitsui, A., Nishiwaki, T., Moriyama, S., Kudo, J., et al. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010320)95:2<92::aid-ijc1016>3.0.co;2-9 · Cited by 345
Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F. L., Albiol, S., Guillem, V., Gallardo, E., Carles, J., Mendez, P., de la Cruz, J. J., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl435 · Cited by 319
ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis
Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., & Dong, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707568200 · Cited by 309
ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C., & Reed, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1512 · Cited by 305
Molecular cloning of a human DNA repair gene
Westerveld, A., Hoeijmakers, J. H. J., van Duin, M., de Wit, J., Odijk, H., Pastink, A., Wood, R. D., & Bootsma, D. (1984) · Nature · doi:10.1038/310425a0 · Cited by 300
Köberle, B., Masters, J. R. W., Hartley, J. A., & Wood, R. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80118-3 · Cited by 300
Self-citationParker, R. J., Eastman, A., Bostick-Bruton, F., & Reed, E. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115080 · Cited by 299
ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair
Ahmad, A., Robinson, A. R., Duensing, A., van Drunen, E., Beverloo, H. B., Weisberg, D. B., Hasty, P., Hoeijmakers, J. H. J., & Niedernhofer, L. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00293-08 · Cited by 299
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286
Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals
Shachar, S., Ziv, O., Avkin, S., Adar, S., Wittschieben, J., Reißner, T., Chaney, S., Friedberg, E. C., Wang, Z., Carell, T., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.281 · Cited by 284
The roles of copper transporters in cisplatin resistance
Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9045-3 · Cited by 283
Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology
Shuck, S. C., Short, E. A., & Turchi, J. J. (2008) · Cell Research · doi:10.1038/cr.2008.2 · Cited by 281
Repair of an Interstrand DNA Cross-link Initiated by ERCC1-XPF Repair/Recombination Nuclease
Kuraoka, I., Kobertz, W. R., Ariza, R. R., Biggerstaff, M., Essigmann, J. M., & Wood, R. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000337200 · Cited by 280
Error-prone bypass of certain DNA lesions by the human DNA polymerase κ
Ohashi, E., Ogi, T., Kusumoto, R., Iwai, S., Masutani, C., Hanaoka, F., & Ohmori, H. (2000) · Genes & Development · doi:10.1101/gad.14.13.1589 · Cited by 278
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
Ferry, K. V., Hamilton, T. C., & Johnson, S. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00441-x · Cited by 275
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., Fumoleau, P., Quan, E., Crown, J., Toppmeyer, D., Smylie, M., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh133 · Cited by 271
Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., Brown, R., & on behalf of the Scottish Gynaecological Clinical Trials Group (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0732 · Cited by 262
Chresta, C. M., Masters, J. R., & Hickman, J. A. (1996) · PubMed · Cited by 261
Song, I.-S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., & Kuo, M. T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1543.3.12 · Cited by 259
The overexpression of specialized DNA polymerases in cancer
Albertella, M. R., Lau, A., & O’Connor, M. J. (2005) · DNA Repair · doi:10.1016/j.dnarep.2005.01.005 · Cited by 250
Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8886 · Cited by 245
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90185-m · Cited by 237
Appleton, K., Mackay, H. J., Judson, I., Plumb, J. A., McCormick, C., Strathdee, G., Lee, C., Barrett, S., Reade, S., Jadayel, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8688 · Cited by 228
Recent Developments in the Field of Anticancer Platinum Complexes
Galanski, M. S. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206777442287 · Cited by 223
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer, C., Mulder, N. H., Timmer‐Bosscha, H., Sluiter, W. J., Meersma, G. J., & de Vries, E. G. E. (1992) · PubMed · Cited by 216
A Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage
Albertella, M. R., Green, C. M., Lehmann, A. R., & O'Connor, M. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1095 · Cited by 207
Kelland, L. R., Sharp, S. Y., O’Neill, C. F., Raynaud, F. I., Beale, P. J., & Judson, I. R. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00141-5 · Cited by 206
Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance
Brozovic, A., & Osmak, M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.007 · Cited by 204
Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η
Alt, A., Lammens, K., Chiocchini, C., Lammens, A., Pieck, J. C., Kuch, D., Hopfner, K.-P., & Carell, T. (2007) · Science · doi:10.1126/science.1148242 · Cited by 203
Wei, S., Chen, C., Strathdee, G., Harnsomburana, J., Shyu, C., Rahmatpanah, F., Shi, H., Ng, S., Yan, P., Nephew, K., et al. (2011) · Newcastle University · doi:10.25405/ncl.34289580 · Cited by 200
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
Mello, J. A., Acharya, S., Fishel, R., & Essigmann, J. M. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90149-0 · Cited by 199
Zhen, W., Link, C. J., O'Connor, P. M., Reed, E., Parker, R., Howell, S. B., & Bohr, V. A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.9.3689 · Cited by 196
Holford, J., Sharp, S., Murrer, B., Abrams, M., & Kelland, L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.59 · Cited by 196
Honecker, F., Wermann, H., Mayer, F., Gillis, A. J. M., Stoop, H., van Gurp, R. J. L. M., Oechsle, K., Steyerberg, E., Hartmann, J. T., Dinjens, W. N. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8623 · Cited by 188
Human Ovarian Cancer and Cisplatin Resistance: Possible Role of Inhibitor of Apoptosis Proteins1
Li, J., Feng, Q., Kim, J.-M., Schneiderman, D., Liston, P., Li, M., Vanderhyden, B., Faught, W., Fung, M. F. K., Senterman, M., et al. (2001) · Endocrinology · doi:10.1210/endo.142.1.7897 · Cited by 185
van der Zee, A. G., Hollema, H., Suurmeijer, A. J., Krans, M., Sluiter, W. J., Willemse, P. H., Aalders, J. G., & de Vries, E. G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.70 · Cited by 184
Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆
Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., & Patrick, S. M. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.03.010 · Cited by 182
Mamenta, E. L., Poma, E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L., & Chaney, S. G. (1994) · PubMed · Cited by 181
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease
Williams, J., Lucas, P. C., Griffith, K. A., Choi, M., Fogoros, S., Hu, Y. Y., & Liu, J. R. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.10.026 · Cited by 173
Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP
Vichi, P. (1997) · The EMBO Journal · doi:10.1093/emboj/16.24.7444 · Cited by 172
Loh, S., Mistry, P., Kelland, L., Abel, G., & Harrap, K. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.419 · Cited by 167
Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
Gossage, L., & Madhusudan, S. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.001 · Cited by 162
Usanova, S., Piée-Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-248 · Cited by 162
Self-citationLi, Q., Yu, J., Mu, C., Yunmbam, M. K., Slavsky, D., Cross, C. L., Bostick-Bruton, F., & Reed, E. (2000) · PubMed · Cited by 161
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
Houldsworth, J., Xiao, H., Murty, V., Chen, W., Ray, B., Reuter, V. E., Bosl, G. J., & Chaganti, R. (1998) · Oncogene · doi:10.1038/sj.onc.1201770 · Cited by 161
Role of copper transporters in the uptake and efflux of platinum containing drugs
Safaei, R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.046 · Cited by 160
Niedernhofer, L. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6540 · Cited by 159
Amantana, A., London, C. A., Iversen, P. L., & Devi, G. R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.699.3.6 · Cited by 153
Mutations of the p53 gene do not occur in testis cancer.
Peng, H., Hogg, D., Malkin, D. M., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M. A. S., Buchanan, J., & Goss, P. E. (1993) · PubMed · Cited by 152
Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review
Yang, P., Ebbert, J. O., Sun, Z., & Weinshilboum, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7110 · Cited by 151
Treiber, D. K., Zhai, X., Jantzen, H., & Essigmann, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5672 · Cited by 151
Jun, H. J., Ahn, M., Kim, H. S., Yi, S. Y., Han, J., Lee, S. K., Ahn, Y. C., Jeong, H.-S., Son, Y.-I., Baek, J.-H., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604464 · Cited by 149
Brozović, A., Fritz, G., Christmann, M., Zisowsky, J., Jaehde, U., Osmak, M., & Kaina, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20522 · Cited by 148
Self-citationJohnson, S. W., Swiggard, P., Handel, L. M., Brennan, J. M., Godwin, A. K., Ozols, R. F., & Hamilton, T. C. (1994) · PubMed · Cited by 135
Handra‐Luca, A., Hernandez, J., Mountzios, G., Clermont, E., Guily, J. L. S., Soria, J., & Fouret, P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0252 · Cited by 135
Cullen, K. J., Newkirk, K. A., Schumaker, L. M., Aldosari, N., Rone, J. D., & Haddad, B. R. (2003) · PubMed · Cited by 133
DNA Repair capacity and cisplatin sensitivity of human testis tumour cells
Köberle, B., Grimaldi, K. A., Sunters, A., Hartley, J. A., Kèlland, L. R., & Masters, J. R. (1997) · International Journal of Cancer · Cited by 132
Self-citationLoss of DNA Polymerase ζ Causes Chromosomal Instability in Mammalian Cells
Wittschieben, J. P., Reshmi, S. C., Gollin, S. M., & Wood, R. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2982 · Cited by 131
Branch, P., Masson, M., Aquilina, G., Bignami, M., & Karran, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203668 · Cited by 126
Overcoming Glutathione S -Transferase P1–Related Cisplatin Resistance in Osteosarcoma
Pasello, M., Michelacci, F., Scionti, I., Hattinger, C. M., Zuntini, M., Caccuri, A. M., Scotlandi, K., Picci, P., & Serra, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5840 · Cited by 125
Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells
Li, Q., Gardner, K. L., Zhang, L., Tsang, B., Bostick-Bruton, F., & Reed, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.36.23419 · Cited by 124
Coquerelle, T. M., Dösch, J., & Kaina, B. (1995) · Mutation Research/DNA Repair · doi:10.1016/0921-8777(94)00035-5 · Cited by 123
Self-citationEmerging cancer therapeutic opportunities target DNA-repair systems
Ding, J., Miao, Z., Meng, L., & Geng, M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.04.007 · Cited by 123
Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human Cells
Papouli, E., Ćejka, P., & Jiricny, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0513 · Cited by 116
Mellish, K. J., Kèlland, L. R., & Harrap, K. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.322 · Cited by 115
Broadening the clinical use of platinum drug–based chemotherapy with new analogues
Kèlland, L. R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1009 · Cited by 112
Wu, F., Lin, X., Okuda, T., & Howell, S. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3942 · Cited by 111
Targeting DNA repair as a promising approach in cancer therapy
Damia, G. L. M., & D’Incalci, M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.05.003 · Cited by 107
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer
Weberpals, J. I., Garbuio, K., O'Brien, A., Clark-Knowles, K. V., Doucette, S. P., Antoniouk, O., Goss, G. D., & Dimitroulakos, J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23987 · Cited by 107
Byun, S., Kim, S. W., Choi, H., Lee, C., & Lee, E. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05472.x · Cited by 105
Belyanskaya, L. L., Hopkins-Donaldson, S., Kurtz, S., Simões‐Wüst, A. P., Yousefi, S., Simon, H., Stahel, R. A., & Zangemeister‐Wittke, U. (2005) · International Journal of Cancer · doi:10.1002/ijc.21242 · Cited by 101
Mismatch repair and treatment resistance in ovarian cancer
Helleman, J., van Staveren, I. L., Dinjens, W. N. M., van Kuijk, P. F., Ruigrok-Ritstier, K., Ewing, P. C., van der Burg, M. E., Stoter, G., & Berns, E. M. J. J. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-201 · Cited by 101
Yang, X., Zheng, F., Xing, H., Gao, Q., Wei, W., Lu, Y., Wang, S., Zhou, J., Hu, W., & Ma, D. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0556-9 · Cited by 100
Tirrò, E., Consoli, M. L., Massimino, M., Manzella, L., Frasca, F., Sciacca, L., Vicari, L., Stassi, G., Messina, L., Messina, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3248 · Cited by 99
Ceppi, P., Novello, S., Cambieri, A., Longo, M., Monica, V., Iacono, M. L., Levra, M. G., Saviozzi, S., Volante, M., Papotti, M. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1227 · Cited by 98
Vaisman, A., & Chaney, S. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.13017 · Cited by 97
Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
Eckardt, J. R., Bentsion, D., Lipatov, O. N., Polyakov, I. S., MacKintosh, F. R., Karlin, D. A., Baker, G. S., & Breitz, H. B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3235 · Cited by 92
Jandial, D. D., Farshchi-Heydari, S., Larson, C., Elliott, G. I., Wrasidlo, W., & Howell, S. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2081 · Cited by 86
Huerta, S., Heinzerling, J. H., Hernández, Y. M. A., Huerta‐Yépez, S., Lin, J., Chen, D. J., Bonavida, B., & Livingston, E. H. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2006.12.551 · Cited by 85
Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic Signaling
Topping, R. P., Wilkinson, J. C., & Scarpinato, K. D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809303200 · Cited by 82
Mismatch repair and response to DNA-damaging antitumour therapies
Bignami, M., Casorelli, I., & Karran, P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00569-0 · Cited by 82
Surowiak, P., Materna, V., Maciejczyk, A., Pudełko, M., Markwitz, E., Spaczyński, M., Dietel, M., Zabel, M., & Lage, H. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0362-7 · Cited by 81
Wang, H., Zhang, S., Wang, S., Lü, J., Wu, W., Weng, L., Chen, D., Zhang, Y., Lu, Z., Yang, H. J., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-015 · Cited by 80
Cruet-Hennequart, S., Glynn, M. T., Murillo, L. S., Coyne, S., & Carty, M. P. (2008) · DNA repair · doi:10.1016/j.dnarep.2007.12.012 · Cited by 79
Mansouri, A., Zhang, Q. C., Ridgway, L. D., Tian, L., & Claret, F.-X. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504003108748410 · Cited by 76
Morgan, A. S., Sanderson, P. E., Borch, R. F., Tew, K. D., Niitsu, Y., Takayama, T., Hoff, D. D. V., Izbicka, E., Mangold, G. L., Paul, C., et al. (1998) · PubMed · Cited by 76
Gadducci, A., Cosio, S., Muraca, S., & Genazzani, A. R. (2002) · PubMed · Cited by 75
Cruet-Hennequart, S., Villalan, S., Kaczmarczyk, A., O’Meara, E., Sokòl, A. M., & Carty, M. P. (2009) · Cell Cycle · doi:10.4161/cc.8.18.9624 · Cited by 69
Johnson, S. W., Shen, D.-W., Pastan, I. H., Gottesman, M. M., & Hamilton, T. C. (1996) · Experimental Cell Research · doi:10.1006/excr.1996.0211 · Cited by 69
Spierings, D. C. J., de Vries, E. G. E., Vellenga, E., & de Jong, S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401248 · Cited by 69
(1999) · PubMed · Cited by 68
DNA Damage Recognition and Nucleotide Excision Repair in Mammalian CellsPreprint
Wood, R. D., Araújo, S. J., Ariza, R. R., Batty, D. P., Biggerstaff, M., Evans, E. L., Gaillard, P.-H. L., Gunz, D., Köberle, B., Kuraoka, I., et al. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.173 · Cited by 65
Self-citationCummings, M., Higginbottom, K., McGurk, C. J., Wong, O. G.-W., Köberle, B., Oliver, R. T. D., & Masters, J. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.04.025 · Cited by 63
Self-citationSurvivin as a predictor of cis‐diamminedichloroplatinum sensitivity in gastric cancer patients
Nakamura, M., Tsuji, N., Asanuma, K., Kobayashi, D., Yagihashi, A., Hirata, K., Torigoe, T., Sato, N., & Watanabe, N. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03169.x · Cited by 63
Kavanagh, J. J., Gershenson, D. M., Choi, H. J., LEWIS, L., PATEL, K., BROWN, G. L., García, A. A., & Spriggs, D. R. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00114.x · Cited by 61
c-Myc and Caspase-2 Are Involved in Activating Bax during Cytotoxic Drug-induced Apoptosis
Cao, X., Bennett, R. L., & May, W. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801107200 · Cited by 61
Down-regulation of DNA polymerases κ, η, ι, and ζ in human lung, stomach, and colorectal cancers
Pan, Q., Fang, Y., Xu, Y., Zhang, K., & Hu, X. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.07.021 · Cited by 61
Hengstler, J. G., Pilch, H., Schmidt, M., Dahlenburg, H., Sagem�ller, J., Schiffer, I. B., Oesch, F., Knapstein, P. G., Kaina, B., & Tanner, B. (2001) · International Journal of Cancer · Cited by 60
Self-citationThe major chromatin protein histone H1 binds preferentially to cis -platinum-damaged DNA
Yaneva, J. N., Leuba, S. H., Holde, K. V., & Zlatanova, J. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13448 · Cited by 60
Alterations of DNA Repair in Melanoma Cell Lines Resistant to Cisplatin, Fotemustine, or Etoposide
Rünger, T. M., Emmert, S., Schadendorf, D., Diem, C., Epe, B., & Hellfritsch, D. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00844.x · Cited by 58
Modulation of Cellular Response to Cisplatin by a Novel Inhibitor of DNA Polymerase β
Boudsocq, F., Benaim, P., Canitrot, Y., Knibiehler, M., Ausseil, F., Capp, J., Bieth, A., Long, C., David, B., Shevelev, I., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.001776 · Cited by 56
Kim, M. K., Cho, K.-J., Kwon, G. Y., Park, S.-I., Kim, Y., Kim, J. H., Song, H.-Y., Shin, J. H., Jung, H., Lee, G. H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4848 · Cited by 52
The Translesion Polymerase Rev3L in the Tolerance of Alkylating Anticancer Drugs
Roos, W. P., Tsaalbi‐Shtylik, A., Tsaryk, R., Güvercin, F., de Wind, N., & Kaina, B. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058131 · Cited by 52
Self-citationBramson, J. L., & Panasci, L. (1993) · PubMed · Cited by 51
Mismatch Repair Status and the Response of Human Cells to Cisplatin
Pani, E., Stojic, L., El‐Shemerly, M., Jiricny, J., & Ferrari, S. M. (2007) · Cell Cycle · doi:10.4161/cc.6.14.4472 · Cited by 47
p53-Induced Apoptosis Occurs in the Absence of p14ARF in Malignant Pleural Mesothelioma
Hopkins-Donaldson, S., Belyanskaya, A. L., Simões‐Wüst, A. P., Sigrist, B., Kurtz, S., Zangemeister‐Wittke, U., & Stahel, R. A. (2006) · Neoplasia · doi:10.1593/neo.06148 · Cited by 47
Role of metallothionein in cisplatin sensitivity of germ-cell tumours
Meijer, C., Timmer, A., de Vries, E. G. E., Groten, J. P., Knol, A., Zwart, N., Dam, W., Sleijfer, D. T., & Mulder, N. H. (2000) · International Journal of Cancer · Cited by 47
Lin, X., Trang, J., Okuda, T., & Howell, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1380 · Cited by 46
Metallothionein levels in ovarian tumours before and after chemotherapy
Murphy, D., McGown, A. T., Crowther, D., Mander, A., & Fox, B. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.160 · Cited by 44
Bedford, P., Walker, M. C., Sharma, H. L., Perera, A., McAuliffe, C. A., Masters, J. R., & Hill, B. T. (1987) · Chemico-Biological Interactions · doi:10.1016/0009-2797(87)90015-9 · Cited by 41
DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells
Massey, A. J., Offman, J., Macpherson, P., & Karran, P. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00187-8 · Cited by 39
Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells
Claij, N., & Riele, H. T. (2004) · Oncogene · doi:10.1038/sj.onc.1207015 · Cited by 37
Biggerstaff, M., & Wood, R. D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50510-5 · Cited by 36
Karczmarek-Borowska, B., Filip, A. A., Wojcierowski, J., Smoleń, A., Pilecka, I., & Jabłonka, A. (2005) · PubMed · doi:10.5603/4604 · Cited by 32
Inactivation of p53 Sensitizes Astrocytic Glioma Cells to BCNU and Temozolomide, but not Cisplatin
Xu, G. W., Mymryk, J. S., & Cairncross, J. G. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-6601-3 · Cited by 29
de Pinho, M. B., Costas, F., de Séllos, J., Dienstmann, R., Andrade, P. B., Herchenhorn, D., Peixoto, F. A., Santos, V. O., Small, I. A., Guimarães, D. P., et al. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.016 · Cited by 18
Cited by
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
DNA repair mechanisms in cancer development and therapy
Torgovnick, A., & Schumacher, B. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00157 · Cited by 396
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 387
Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin
Aldossary, S. A. (2019) · Biomedical and Pharmacology Journal · doi:10.13005/bpj/1608 · Cited by 366
Metadata
- Authors
- Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 1806
- Issue
- 2
- Pages
- 172-182
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2042083290
- Cited by
- 361
- References
- 150
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.